» Articles » PMID: 31028668

Birthweight Correlates with Later Metabolic Abnormalities in Chinese Patients with Maturity-onset Diabetes of the Young Type 2

Overview
Journal Endocrine
Specialty Endocrinology
Date 2019 Apr 28
PMID 31028668
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Glucokinase-maturity onset diabetes of the young (GCK-MODY), also known as MODY2, is caused by heterozygous inactivating mutations in the GCK gene. The aim of this study is to investigate the relationship of birthweight and cardiometabolic characteristics in MODY2 patients.

Methods: Genetic screening for GCK mutations from 192 classical MODY families was performed, and birthweight and clinical profiles of 76 patients from 25 families with identified GCK mutations were collected.

Results: Mutations in GCK were identified in 25 (13%) of the 192 families. Four novel (c.1334 G > C, c.1289_1294delTGACGC, c.584 T > C, and c.30delC) and twenty-one previously reported mutations were identified and cosegregated with the clinical phenotypes of MODY2 within the pedigrees. MODY2 patients presented a mean birthweight of 3.11 ± 0.44 kg. Additionally, birthweight was negatively correlated with 2 h-postprandial glucose (r = -0.426, P = 0.006), glycated albumin (r = -0.462, P = 0.035), glycated hemoglobin (r = -0.529, P = 0.001), total cholesterol (r = -0.430, P = 0.016), and low-density lipoprotein cholesterol (LDL-C) (r = -0.383, P = 0.033) levels after adjustment for age, gender and BMI. Importantly, among the patients who inherited mutations from their mothers, 7 patients whose mothers were treated with insulin during pregnancy had particularly lower birthweight (2.83 ± 0.39 vs. 3.37 ± 0.39 kg; P = 0.003), higher total cholesterol (6.15 ± 0.43 vs. 4.06 ± 0.16 mmol/L; P = 0.002) and LDL-C (4.05 ± 0.35 vs. 2.21 ± 0.13 mmol/L; P = 0.001) levels compared to the other 21 patients whose mothers received no treatment.

Conclusions: The correlations between birthweight and cardiometabolic indexes indicated that MODY2 patients with lower birthweight (<3.1 kg) should be monitored and treated more actively to prevent metabolic abnormalities, particularly dyslipidemia. Importantly, prenatal genic diagnosis is highly recommended to avoid inappropriate treatment in pregnancy leading to lower birthweight of offspring.

Citing Articles

Pregnancy and neonatal outcomes in women with GCK-MODY: an observational study based on standardised insulin modalities.

Ciangura C, Seco A, Saint-Martin C, Ancel P, Bouvet D, Jacqueminet S Diabetologia. 2025; .

PMID: 39971752 DOI: 10.1007/s00125-025-06363-0.


A Case of 17q12 Microdeletion Syndrome in a MODY5 Type Diabetes with HNF-1β Gene Mutation Accompanied.

Zhang S, Ma Y, Zang X, Heng H, Liu X, Peng G Appl Clin Genet. 2024; 17:125-130.

PMID: 39050772 PMC: 11268705. DOI: 10.2147/TACG.S465859.


Management of monogenic diabetes in pregnancy: A narrative review.

Jeeyavudeen M, Murray S, Strachan M World J Diabetes. 2024; 15(1):15-23.

PMID: 38313847 PMC: 10835499. DOI: 10.4239/wjd.v15.i1.15.


GCK-MODY in pregnancy: A pregnant woman with diabetes and a small-for-gestational-age fetus.

Yau T, Yu S, Cheng J, Kwok J, Ma R Clin Case Rep. 2022; 10(12):e6629.

PMID: 36483860 PMC: 9723257. DOI: 10.1002/ccr3.6629.


The Challenges of Treating Glucokinase MODY during Pregnancy: A Review of Maternal and Fetal Outcomes.

Kirzhner A, Barak O, Vaisbuch E, Zornitzki T, Schiller T Int J Environ Res Public Health. 2022; 19(10).

PMID: 35627517 PMC: 9141824. DOI: 10.3390/ijerph19105980.


References
1.
Fendler W, Rizzo M, Borowiec M, Malachowska B, Antosik K, Szadkowska A . Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol. 2014; 51(4):625-32. PMC: 4127439. DOI: 10.1007/s00592-014-0567-1. View

2.
Girard J, Ferre P, Foufelle F . Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr. 1997; 17:325-52. DOI: 10.1146/annurev.nutr.17.1.325. View

3.
Shehadeh N, Bakri D, Njolstad P, Gershoni-Baruch R . Clinical characteristics of mutation carriers in a large family with glucokinase diabetes (MODY2). Diabet Med. 2005; 22(8):994-8. DOI: 10.1111/j.1464-5491.2005.01555.x. View

4.
Wang X, Wang T, Yu M, Zhang H, Ping F, Zhang Q . Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young. Acta Diabetol. 2018; 56(3):281-288. DOI: 10.1007/s00592-018-1232-x. View

5.
Barrio R, Bellanne-Chantelot C, Moreno J, Morel V, Calle H, Alonso M . Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab. 2002; 87(6):2532-9. DOI: 10.1210/jcem.87.6.8530. View